Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q3 FY2024 Earnings Presentation
25 slides from Piramal Pharma's earnings presentation, January 2024
Slide 1: Piramal Pharma Limited Q3 & 9M FY2024 Results
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Piramal Pharma Limited Q3 & 9M FY2024 Results January 2024
Slide 2: Disclaimer
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 2 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, r
Slide 3: Key Performance Highlights of Q3 and 9M FY2024
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 3 Key Performance Highlights of Q3 and 9M FY2024
Slide 4: Key Highlights of Q3 and 9M FY2024
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 4 Key Highlights of Q3 and 9M FY2024 ❖ Revenue from Operations grew by 14% YoY in both Q3 FY2024 and in 9M FY2024 YoY Revenue Growth Business Segment Q3 FY2024 9M FY2024 Contract Development and Manufacturing (CDMO) 12% 14% Complex Ho
Slide 5: Financial Performance in Q3 and 9M FY2024
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 5 Financial Performance in Q3 and 9M FY2024 Q3 FY2024 9M FY2024 Net Debt / EBITDA* (In INR Crore) Revenue EBITDA Revenue 14% YoY Revenue 14% YoY Improving Net Debt / EBITDA EBITDA 94% YoY EBITDA 71% YoY 5.6 5,619 5.0 4,918 3.7 3.4 1,9
Slide 6: Business-wise Performance
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 6 Business-wise Performance
Slide 7: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 7 Contract Development and Manufacturing Organization Business Performance Highlights Revenue performance in Q3 FY2024 (In INR Crore) ❖ Continued momentum in order inflows in 9M FY2024: • Despite challenging funding environment, our n
Slide 8: Continue to Maintain Best-in-Class Quality Track Record
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 8 Continue to Maintain Best-in-Class Quality Track Record 300+ Regulatory Inspections# since FY12 with zero OAI* ~125 audits annually by customers USFDA Inspections 44 Customer Audits Total Regulatory Inspections 35 36 29 29 197 26 27
Slide 9: Growth Drivers for CDMO Business
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 9 Growth Drivers for CDMO Business Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Pursue inorganic growth Customer ❑ Focus on expanding Capability technical/product capabilities and to offer integrated services Capaci
Slide 10: Complex Hospital Generics Business
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 10 Complex Hospital Generics Business Performance Highlights Revenue growth in Q3 FY2024 (In INR Crore) ❖ YoY revenue growth in Q3 and 9M FY2024 driven by: • Volume growth in the inhalation anaesthesia portfolio in the US, partly offs
Slide 11: Growth Drivers for CHG Business
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 11 Growth Drivers for CHG Business Near-term Visible Revenue Growth Levers Upsides Beyond the Plan Business acquisitions Vertical Differentiated integration portfolio ❑ Carrying out synergistic Strong pipeline product and business ❑ C
Slide 12: India Consumer Healthcare Business
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 12 India Consumer Healthcare Business Performance Highlights Revenue growth in Q3 FY2024 ❖ New Product launches - 6 new products and 3 new SKUs launched in Q3 FY2024. New (In INR Crore) products launched in last 24 months contribute t
Slide 13: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 13 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing Investments in brand promotion and marketing Strong growth in our power brands (In INR Crore) % of ICH sales (In INR Crore) 38% CAGR 16% 15% 15% 13%
Slide 14: Leverage Multi-channel Distribution Network and New Product Launches
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 14 Leverage Multi-channel Distribution Network and New Product Launches Presence across traditional and alternate trade channels Regular new product launches contributing to growth Presence in ~180K chemists and cosmetics stores and 1
Slide 15: Abbvie Therapeutics India Private Limited
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 15 Abbvie Therapeutics India Private Limited* Joint Venture Arrangement Ownership Ownership 49% 51% In FY2023, the JV reported# revenue of Rs.446Cr with PAT margin of 25% Continue to be one of Key Brands the market leaders in 400+ Str
Slide 16: Sustainability Initiatives
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 16 Sustainability Initiatives
Slide 17: Key Sustainability Highlights
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 17 Key Sustainability Highlights Climate Change Management Piramal Pharma has taken a target to reduce it’s Scope 1 and 2 GHG emissions by 42% by FY2030 with a baseline of FY2022. This is in-line with the SBTI’s# 1.5o C pathway to lim
Slide 18: Key Sustainability Highlights
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 18 Key Sustainability Highlights Waste Management Afforestation Responsible Supply Chain On track to achieve Zero Planted 2,400+ trees and Released PPL Sustainable Chain Policy Hazardous Waste to sapling in 9M FY2024 Conducted capacit
Slide 19: Key Sustainability Highlights
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 19 Key Sustainability Highlights Committed to SBTi Climate Change and Member of UNGC Member of PSCI Water Security Disclosures “We will continue to make judicious investments to expand sustainable practices across our operations to mi
Slide 20: Key Strategic Priorities
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 20 Key Strategic Priorities
Slide 21: Key Strategic Priorities
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 21 Key Strategic Priorities 1 Drive demand in CDMO business by increasing the proposal velocity and win rate 2 Delivering consistent revenue growth and improving profitability Track record of 3 Pursuing organic and inorganic growth op
Slide 22: Financials
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 22 Financials
Slide 23: Consolidated Financials Highlights
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 23 Consolidated Financials Highlights (In INR Crores or as stated) Particulars Q3 FY2024 Q3 FY2023 YoY Change Q2 FY2024 QoQ Change Revenue from Operations* 1,959 1,716 14% 1,911 2% CDMO 1,134 1,010 12% 1,068 6% CHG 576 514 12% 589 (2)
Slide 24: Dial-in details for Q3 and 9M FY2024 Earnings Conference Call
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 24 Dial-in details for Q3 and 9M FY2024 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 05:00 PM IST 1 800 120 1221 (Toll free number) USA – 06:30 AM Toll fr
Slide 25: For Investor Queries
Piramal Pharma Limited – Q3 & 9M FY2024 Results Presentation Page 25 For Investor Queries: Gagan Borana General Manager – Investor Relations & Sustainability Email : gagan.borana@piramal.com Phone : +91 22 3802 3090